A Study of Microcirculatory Function as the Mechanism of Type 2 Myocardial Infarction

Overview

About this study

The purpose of this study is to determine if coronary microvascular disease (CMD) is part of the pathophysiology of type 2 myocardial infarction (T2MI).  Also, to see if patients with T2MI without significant epicardial coronary artery disease have CMD, defined as coronary flow reserve (CFR) <2.5 or inability to increase coronary flow by 50% or greater during Acetylcholine infusion.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age.
  • Ability to give informed consent.
  • Structurally normal heart (normal LV and RV function, no more than mild valvular heart disease).

For Controls:

  • typical chest pain with indication for CMD testing.

For T2MI:

  • Meet criteria for T2MI according to the 4th Universal definition of MI (rise/fall of troponin with at least 1 value > 99th centile+ evidence of symptoms or signs of myocardial ischemia).

Exclusion Criteria:

  • Acute coronary event (evidence of plaque rupture, fissure or dissection on coronary angiogram).
  • Known to have angiographically significant CAD/pressure wire positive for epicardial CAD.
  • Hb<8 within 1 week of study enrollment.
  • Inability to receive heparin products.
  • Allergy/contraindication to acetylcholine/adenosine/nitroglycerine products.
  • Prior coronary artery bypass grafting.
  • Pregnancy (if sexually active woman of reproductive age, need negative pregnancy test prior to proceeding with coronary angiography – this is standard of care in cath lab).
  • Asthma with prior ICU admission due to bronchospasm/need for invasive ventilation.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/5/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Claire Raphael, M.B.B.S., Ph.D.

Contact us for the latest status

Contact information:

Ischemic Heart Disease (IHD)

(507) 284-4256

More information

Publications

Publications are currently not available